Due to the unprecedented nature of the COVID-19 pandemic, anyone reporting an Adverse Event and/or a Product Complaint via phone, should you receive a network busy signal (ie: if all lines busy/engaged) please continue to try your call throughout the day. Alternatively, you may email your Adverse Event to drugsafety@propharmagroup.com OR Product Complaint to productcomplaint@propharmagroup.com, OR medical information request to MedInfo@propharmagroup.com.

Esmolol HCI in Water for Injection

Therapeutic Category: Cardiovascular Agent

AVAILABLE in a READY-TO-USE formulation

  • A Clear Choice for STAT dosing
    • Ready-to-use in a clear bag when removed from overwrap for immediate dosing
    • Clear bag allows immediate visual inspection for particulate matter
  • Does not contain sodium chloride1
  • Osmolarity/osmolality is comparable to other commonly used drugs2-5
  • Bag and bag ports are free of natural rubber latex, DEHP, and PVC1

To order WGCC products, please contact your wholesaler or call Customer Service at 1-888-493-0861.


NDC # Total Amount Fill Volume Container Type Concentration Pack Size Package Insert
44567-811-10 2500 mg/250 mL 250 mL Premixed Bag 10 mg/mL 10 Bag Carton
44567-812-10 2000 mg/100 mL
DOUBLE STRENGTH
100 mL Premixed Bag 20 mg/mL 10 Bag Carton
Indication and Usage
Product Characteristics
Osmolarity/Osmolality
Unique Attributes

INDICATIONS AND USAGE

Esmolol Hydrochloride is a beta-adrenergic blocker used for the short-term treatment of:

  • Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia
  • Control of perioperative tachycardia and hypertension

IMPORTANT SAFETY INFORMATION

CONTRAINDICATED IN: severe sinus bradycardia; heart block greater than first degree; sick sinus syndrome; decompensated heart failure; cardiogenic shock; coadministration of IV cardiodepressant calcium-channel antagonists (e.g. verapamil) in close proximity to esmolol; pulmonary hypertension; known hypersensitivity to esmolol.

WARNINGS AND PRECAUTIONS

RISK OF: hypotension, bradycardia, cardiac failure; exacerbating reactive airway disease; unopposed alpha-agonism and severe hypertension in untreated pheochromocytoma; myocardial ischemia when abruptly discontinued in patients with coronary artery disease. In diabetes mellitus, increases the effect of hypoglycemic agents and masks hypoglycemic tachycardia. The most common adverse reactions (incidence >10%) are symptomatic and asymptomatic hypotension. Drug interactions may occur with digitalis glycosides, anticholinesterases, antihypertensive agents, sympathomimetic drugs, and vasoconstrictive and positive inotropic effect substances.

Please see the package insert for complete prescribing information.

*BREVIBLOC® is a registered trademark of Baxter International Inc., or it’s subsidiaries.

References
1. Esmolol Hydrochloride in Water for Injection [prescribing information]. WG Critical Care, LLC; Paramus, NJ. April 2016. 2. Brevibloc (esmolol hydrochloride) [prescribing information]. Baxter Healthcare Corporation; Deerfield, IL. April 2014. 3. AHFS Drug Information 2018. 1st edition. ASHP; Bethesda, MD. 4. Trissel LA. Handbook on Injectable Drugs. 16th edition. ASHP; Bethesda, MD. 5. Gahart Bl, Nazareno AR. Gahart’s 2018 Intravenous Medications: A Handbook for Nurses and Health Professionals. 34th edition. Mosby; St. Louis, MO.

Esmolol HCl in WFI Contains the Same Active Ingredient As Brevibloc (esmolol HCl) Injection*, Without Sodium Chloride

Esmolol HCl in WFI Has Similar Product Characteristics to Brevibloc1-2

chart-generic

References
1. Esmolol Hydrochloride in Water for Injection [prescribing information]. WG Critical Care, LLC; Paramus, NJ. April 2016. 2. Brevibloc (esmolol hydrochloride) [prescribing information]. Baxter Healthcare Corporation; Deerfield, IL. April 2014. 3. AHFS Drug Information 2018. 1st edition. ASHP; Bethesda, MD. 4. Trissel LA. Handbook on Injectable Drugs. 16th edition. ASHP; Bethesda, MD. 5. Gahart Bl, Nazareno AR. Gahart’s 2018 Intravenous Medications: A Handbook for Nurses and Health Professionals. 34th edition. Mosby; St. Louis, MO.

Osmolarity/Osmolality of WGCC Esmolol HCl in WFI Is In Range of Other Commonly Used Products3

barchart

*Represented as osmolality (mOsmol/L)
†Represented as osmolarity (mOsm/L)

References
1. Esmolol Hydrochloride in Water for Injection [prescribing information]. WG Critical Care, LLC; Paramus, NJ. April 2016. 2. Brevibloc (esmolol hydrochloride) [prescribing information]. Baxter Healthcare Corporation; Deerfield, IL. April 2014. 3. AHFS Drug Information 2018. 1st edition. ASHP; Bethesda, MD. 4. Trissel LA. Handbook on Injectable Drugs. 16th edition. ASHP; Bethesda, MD. 5. Gahart Bl, Nazareno AR. Gahart’s 2018 Intravenous Medications: A Handbook for Nurses and Health Professionals. 34th edition. Mosby; St. Louis, MO.

Esmolol HCl in WFI Has Unique Attributes vs Brevibloc1-2

chart-compare

Esmolol HCl in WFI Is a Clear Choice For STAT Dosing

  • Ready-to-use in a clear bag when removed from overwrap for immediate dosing
  • Clear bag allows immediate visual inspection for particulate matter

References
1. Esmolol Hydrochloride in Water for Injection [prescribing information]. WG Critical Care, LLC; Paramus, NJ. April 2016. 2. Brevibloc (esmolol hydrochloride) [prescribing information]. Baxter Healthcare Corporation; Deerfield, IL. April 2014. 3. AHFS Drug Information 2018. 1st edition. ASHP; Bethesda, MD. 4. Trissel LA. Handbook on Injectable Drugs. 16th edition. ASHP; Bethesda, MD. 5. Gahart Bl, Nazareno AR. Gahart’s 2018 Intravenous Medications: A Handbook for Nurses and Health Professionals. 34th edition. Mosby; St. Louis, MO.

WG Critical Care Product Catalog

To order WGCC products, please contact your wholesaler or call Customer Service at 1-888-493-0861.
© 2020 WG Critical Care, LLC | A PharmaSphere Company | 120 Rte 17 N, Paramus, NJ 07652